What is Adaptive Biotechnologies Corporation's (ADPT) StockRank?

MoatMap's StockRank for Adaptive Biotechnologies Corporation (ADPT) is 38/100, with a Hold signal. This is a composite score combining Quality (40), Value (21), and Momentum (70) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Adaptive Biotechnologies Corporation have an economic moat?

Adaptive Biotechnologies Corporation (ADPT) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Adaptive Biotechnologies Corporation a buy, hold, or sell?

MoatMap's current signal for Adaptive Biotechnologies Corporation (ADPT) is Hold, based on a StockRank of 38/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Adaptive Biotechnologies Corporation in?

Adaptive Biotechnologies Corporation (ADPT) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ADPT

HoldHot Air

Adaptive Biotechnologies Corporation · Healthcare · United States · $4.0B · Avg Vol: $51M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-38.8%

D/E

2.7x

Dividend %

—

COMPANY DESCRIPTION

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that sequences the adaptive immune system to develop clinical diagnostics and drug discovery solutions. It holds a proprietary immune medicine platform that analyzes T-cell and B-cell receptor repertoires, providing unparalleled insights into the immune system for disease detection and drug development. Adaptive is a leader in immune sequencing technology, aiming to transform disease diagnosis and treatment by leveraging the power of the adaptive immune system.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	185.3M	170.3M	179.0M	277.0M	14.3%	308.1M	293.2M	358.5M	13.8%
EPS	-1.40	-1.56	-1.08	-0.39	—	-0.40	-0.54	-0.18	—
Shares	143.1M	145.1M	147.8M	153.8M	+7.5%	159.6M	—	—	—
Debt	108.0M	98.8M	89.4M	79.1M	-9.8%	410.5M	—	—	—
Equity	464.2M	308.4M	202.7M	218.8M	-22.2%	—	—	—	—
Op CF	-183.9M	-156.3M	-95.2M	-46.0M	—	-21.0M	—	—	—
Inv CF	2.9M	129.6M	77.8M	38.0M	—	—	—	—	—
Fin CF	132.3M	2.2M	0.2M	30.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+0.2%

SMA 50SMA 200

$24.23

RSI (14)

38.3

52W High

$26.87

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-11.3%33.9

ROE

-38.8%22.1

GP/Assets

28.2%60.6

Op. Margin

-22.0%24.4

FCF/Assets

n/mN/A

Piotroski

668.6

Int. Cover

-4.0x28.3

D/E Ratio

2.72x3.7

Current Ratio

4.79x71.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-185.2x25.0

P/FCF

n/mN/A

P/B

27.0x3.6

P/S

12.6x22.4

Div Yield

—N/A

Momentum

52W High %

90%87.4

RS 6M

58%93.0

SMA 50/200

1.33x94.3

EPS Rev 4W

-3.2%17.1

EPS Rev 12W

+28.2%93.9

EPS Improve

+54%57.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$4.0B

P/E (Forward)

-131.4x

Gross Margin

46.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ADPT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ADPT	Adaptive Biotechnologies Corporation(you)	$4.0B	38	Hold
RDNT	RadNet, Inc.	$5.9B	34	Sell
GRAL	GRAIL, Inc.	$3.6B	28	Sell
NEO	NeoGenomics, Inc.	$2.3B	47	Hold
WGS	GeneDx Holdings Corp.	$2.6B	24	Sell
BLLN	BillionToOne, Inc.	$4.4B	61	Hold
TWST	Twist Bioscience Corporation	$8.9B	47	Hold
OPK	OPKO Health, Inc.	$1.1B	38	Hold
CSTL	Castle Biosciences, Inc.	$1.0B	39	Hold
PSNL	Personalis, Inc.	$1.8B	24	Sell

Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%

Adaptive Biotechnologies Corporation (ADPT): Stock Score Summary

Adaptive Biotechnologies Corporation (ADPT) has a MoatMap StockRank of 38/100 based on Quality (40/100), Value (21/100), and Momentum (70/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$24.23
Market Cap	$4.0B
P/E (Forward)	-131.44
Price/Book	27.04
Return on Equity	-38.8%
Return on Invested Capital	-11.3%
Debt/Equity	2.72x
Gross Margin	46.9%
Operating Margin	-22.0%
Revenue Growth	21.5%
Free Cash Flow	$19M

Adaptive Biotechnologies Corporation operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Adaptive Biotechnologies Corporation’s (ADPT) StockRank?: MoatMap’s StockRank for Adaptive Biotechnologies Corporation (ADPT) is 38/100, with a Hold signal. It is a composite of Quality (40), Value (21), and Momentum (70) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Adaptive Biotechnologies Corporation have an economic moat?: Adaptive Biotechnologies Corporation (ADPT) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Adaptive Biotechnologies Corporation a buy, hold, or sell?: MoatMap’s current signal for Adaptive Biotechnologies Corporation (ADPT) is Hold, based on a StockRank of 38/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Adaptive Biotechnologies Corporation in?: Adaptive Biotechnologies Corporation (ADPT) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).